Received Jun 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y018389 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
Caller stated patient did not report any symptoms.; patient who is currently 19 years old received their 1st dose of GARDASIL 9 in 2018 and their 2nd dose on 3/27/2025.; This spontaneous report was received from a pharmacist and refers to a 19-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. In 2018, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (lot #, expiration date, dose, frequency, route of administration and anatomical location of vaccine were not reported); on 27-MAR-2025, the patient received the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), lot #Y018389, expiration date was not reported, but upon internal validation was established as 04-NOV-2026 (dose, route of administration and anatomical location of vaccine were not reported) (inappropriate schedule of drug administration); both doses were administrated for Prophylaxis. The reporter stated that the patient experienced Caller stated patient did not report any symptoms (No adverse event).